ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced full-year 2025 financial and operational highlights, including approximately $113 million in net product ...

ImmunityBio, Inc.: ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with ...

ANKTIVA net product revenue increased 20% quarter-over-quarter, with full-year net product revenue of $113 million, representing an approximately 700% increase year-over-year ...